JP2011512160A - ポリオーマウイルスの検出 - Google Patents
ポリオーマウイルスの検出 Download PDFInfo
- Publication number
- JP2011512160A JP2011512160A JP2010547632A JP2010547632A JP2011512160A JP 2011512160 A JP2011512160 A JP 2011512160A JP 2010547632 A JP2010547632 A JP 2010547632A JP 2010547632 A JP2010547632 A JP 2010547632A JP 2011512160 A JP2011512160 A JP 2011512160A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amplification
- polyomavirus
- step comprises
- testing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001505332 Polyomavirus sp. Species 0.000 title claims abstract description 28
- 238000001514 detection method Methods 0.000 title description 9
- 238000000034 method Methods 0.000 claims abstract description 88
- 238000012360 testing method Methods 0.000 claims abstract description 47
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 41
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 39
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 39
- 230000000295 complement effect Effects 0.000 claims abstract description 18
- 239000000523 sample Substances 0.000 claims description 116
- 108020004414 DNA Proteins 0.000 claims description 99
- 230000003321 amplification Effects 0.000 claims description 68
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 68
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 34
- 239000002751 oligonucleotide probe Substances 0.000 claims description 34
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 29
- 102000053602 DNA Human genes 0.000 claims description 7
- 238000011880 melting curve analysis Methods 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 5
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 229960000724 cidofovir Drugs 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 2
- 229960000681 leflunomide Drugs 0.000 claims description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 2
- 210000002216 heart Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 241000829111 Human polyomavirus 1 Species 0.000 description 81
- 241000701460 JC polyomavirus Species 0.000 description 59
- 238000002844 melting Methods 0.000 description 18
- 230000008018 melting Effects 0.000 description 18
- 238000009396 hybridization Methods 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 15
- 238000003556 assay Methods 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 108091093088 Amplicon Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 108020005202 Viral DNA Proteins 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- 101150093578 VP2 gene Proteins 0.000 description 5
- 238000013207 serial dilution Methods 0.000 description 5
- 101150090724 3 gene Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 238000012408 PCR amplification Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000000137 annealing Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710197658 Capsid protein VP1 Proteins 0.000 description 2
- 101710081079 Minor spike protein H Proteins 0.000 description 2
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 2
- 101710118046 RNA-directed RNA polymerase Proteins 0.000 description 2
- 101150024766 VP1 gene Proteins 0.000 description 2
- 101710108545 Viral protein 1 Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- ACOJCCLIDPZYJC-UHFFFAOYSA-M thiazole orange Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.C1=CC=C2C(C=C3N(C4=CC=CC=C4S3)C)=CC=[N+](C)C2=C1 ACOJCCLIDPZYJC-UHFFFAOYSA-M 0.000 description 2
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000001963 scanning near-field photolithography Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6416608P | 2008-02-20 | 2008-02-20 | |
| PCT/US2009/001032 WO2009105212A2 (en) | 2008-02-20 | 2009-02-19 | Detection of polyomavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011512160A true JP2011512160A (ja) | 2011-04-21 |
| JP2011512160A5 JP2011512160A5 (enExample) | 2013-03-21 |
Family
ID=40986099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547632A Pending JP2011512160A (ja) | 2008-02-20 | 2009-02-19 | ポリオーマウイルスの検出 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110091866A1 (enExample) |
| JP (1) | JP2011512160A (enExample) |
| KR (1) | KR20110011600A (enExample) |
| CN (1) | CN102066580A (enExample) |
| WO (1) | WO2009105212A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020501600A (ja) * | 2016-11-09 | 2020-01-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂｋウイルスの検出のための組成物および方法 |
| JP2022508954A (ja) * | 2018-10-22 | 2022-01-19 | ジェン－プローブ・インコーポレーテッド | ヒトポリオーマウイルスｂｋウイルスを増幅、検出または定量化するための組成物および方法 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012143427A1 (en) * | 2011-04-19 | 2012-10-26 | Santaris Pharma A/S | Anti polyomavirus compounds |
| CN102690894B (zh) * | 2011-06-08 | 2013-05-01 | 中国人民解放军第三〇九医院 | 一种bk病毒的检测方法、其试剂盒及应用 |
| AU2012284122B2 (en) | 2011-07-18 | 2017-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for inhibiting polyomavirus-associated pathology |
| CN102690895B (zh) * | 2011-07-27 | 2013-05-01 | 中国人民解放军第三〇九医院 | 一种jc病毒的检测试剂盒及应用 |
| EP2888366A4 (en) * | 2012-08-22 | 2016-03-30 | Univ California | NEW POLYMAVIRUS ASSOCIATED WITH DIARRHOE IN CHILDREN |
| CN104745723A (zh) * | 2015-01-30 | 2015-07-01 | 湖北永邦医疗科技有限公司 | 一种用于检测bk病毒的引物、探针和试剂盒 |
| CN106065420A (zh) * | 2016-07-29 | 2016-11-02 | 北京思尔成生物技术有限公司 | Bk病毒的检测方法、试剂盒及其应用 |
| FR3082524B1 (fr) * | 2018-06-18 | 2022-03-25 | Univ Paris Sud | Methode de stratification du risque de nephropathie a bk-virus apres transplantation renale |
| KR20210047716A (ko) | 2019-10-22 | 2021-04-30 | 단국대학교 천안캠퍼스 산학협력단 | Jc 바이러스를 검출하기 위한 등온증폭 반응용 프라이머 세트 및 이의 용도 |
| CN112522440A (zh) * | 2020-11-13 | 2021-03-19 | 苏州奥根诊断科技有限公司 | 同时检测bk病毒和jc病毒的引物组和探针组及用途 |
| CN113999937B (zh) * | 2021-11-04 | 2024-07-26 | 领致生物科技(昆山)有限公司 | 一种检测bk病毒和jc病毒的试剂及应用 |
| CN115216563A (zh) * | 2022-06-20 | 2022-10-21 | 广东永诺医疗科技有限公司 | 一种用于检测jc病毒的引物、探针及试剂盒 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605602B1 (en) * | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| WO2007016275A2 (en) * | 2005-08-02 | 2007-02-08 | Focus Diagnostics, Inc. | Methods and compositions for detecting bk virus |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) * | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5210015A (en) * | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| US20060205040A1 (en) * | 2005-03-03 | 2006-09-14 | Rangarajan Sampath | Compositions for use in identification of adventitious viruses |
-
2009
- 2009-02-19 US US12/918,055 patent/US20110091866A1/en not_active Abandoned
- 2009-02-19 JP JP2010547632A patent/JP2011512160A/ja active Pending
- 2009-02-19 WO PCT/US2009/001032 patent/WO2009105212A2/en not_active Ceased
- 2009-02-19 CN CN2009801129619A patent/CN102066580A/zh active Pending
- 2009-02-19 KR KR1020107020518A patent/KR20110011600A/ko not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605602B1 (en) * | 2001-09-28 | 2003-08-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Method of treating BK virus nephropathy |
| WO2007016275A2 (en) * | 2005-08-02 | 2007-02-08 | Focus Diagnostics, Inc. | Methods and compositions for detecting bk virus |
Non-Patent Citations (3)
| Title |
|---|
| JPN6013053275; Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ Ｖｉｒｏｌｏｇｙ Ｖｏｌ．３６, 2006, ｐ．１５９-１６２ * |
| JPN6013053276; ＧｅｎＢａｎｋ［ｏｎｌｉｎｅ］ Ａｃｃｅｓｓｉｏｎ Ｎｏ．ＮＣ＿００１５３８．１, 20071204 * |
| JPN6013053279; Ｊｏｕｒｎａｌ ｏｆ Ｖｉｒｏｌｏｇｉｃａｌ Ｍｅｔｈｏｄｓ Ｖｏｌ．１３５, 2006, ｐ．２０７-２１３ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020501600A (ja) * | 2016-11-09 | 2020-01-23 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂｋウイルスの検出のための組成物および方法 |
| JP2022508954A (ja) * | 2018-10-22 | 2022-01-19 | ジェン－プローブ・インコーポレーテッド | ヒトポリオーマウイルスｂｋウイルスを増幅、検出または定量化するための組成物および方法 |
| JP7542546B2 (ja) | 2018-10-22 | 2024-08-30 | ジェン－プローブ・インコーポレーテッド | ヒトポリオーマウイルスｂｋウイルスを増幅、検出または定量化するための組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110091866A1 (en) | 2011-04-21 |
| WO2009105212A3 (en) | 2010-04-22 |
| WO2009105212A2 (en) | 2009-08-27 |
| CN102066580A (zh) | 2011-05-18 |
| KR20110011600A (ko) | 2011-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011512160A (ja) | ポリオーマウイルスの検出 | |
| Watzinger et al. | Detection and monitoring of virus infections by real-time PCR | |
| KR102246600B1 (ko) | 핵산 검정에서 개선된 용융 판별 및 멀티플렉싱을 위한 프로브 | |
| US20030157499A1 (en) | Method of assessing the amount of nucleic acid in a sample | |
| US6355433B1 (en) | Determination of nucleotide sequence variations through limited primer extension | |
| JP4571857B2 (ja) | Ｂ型肝炎ウイルスの核酸の検出および定量のためのポリヌクレオチド | |
| US20070281295A1 (en) | Detection of human papillomavirus E6 mRNA | |
| JP2013516984A (ja) | 試料中の異常核酸の増幅を確実にするための方法 | |
| JP6181742B2 (ja) | Ｈｅｖアッセイ | |
| JP5593582B2 (ja) | 核酸の迅速な検出方法 | |
| BR112017006905B1 (pt) | Conjunto de oligonucleotídeos, método para detectar e discriminar alvos htlv1/2 e kit para diagnóstico e discriminação da infecção pelo htlv1/2 | |
| JP4969250B2 (ja) | スペーサー領域を使用するプロテウス種の検出、同定、および区別 | |
| Wang et al. | Application of molecular beacons in real-time PCR | |
| CN106319079B (zh) | 一种检测22q11.2拷贝数缺失的方法 | |
| US20240124947A1 (en) | Compositions for coronavirus detection and methods of making and using therof | |
| JP7651826B2 (ja) | ＳＡＲＳ－ＣｏＶ－２検出用オリゴヌクレオチド及びその用途 | |
| US20160024563A1 (en) | Method for performing a melting curve analysis | |
| KR102599751B1 (ko) | 돼지 급성설사 증후군 코로나바이러스 검출용 프라이머 세트 | |
| JP6673832B2 (ja) | アッセイ認識のための多重ｐｃｒ反応のコード化法 | |
| Devi et al. | Real Time PCR as a Diagnostic Tool in Biomedical Sciences | |
| JP7697201B2 (ja) | インフルエンザウイルス検出用オリゴヌクレオチド及びその用途 | |
| JP7589434B2 (ja) | Ｂｏｒｄｅｔｅｌｌａ属菌の検出方法 | |
| KR20190100675A (ko) | Sfts 바이러스 검출용 올리고뉴클레오티드 세트 및 이의 용도 | |
| WO2009087688A2 (en) | Method for detection of nucleic acid of mycobacterium and uses thereof | |
| US20230287523A1 (en) | Sars-cov-2 rapid sequence-based diagnostic assay with sensors of immune activation and the viral microbiota |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110304 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120130 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130117 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131028 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140324 |